Gastroesophageal Reflux Disease Market Size

Gastroesophageal Reflux Disease Market size was over USD 5.12 Billion in 2023 and is anticipated to reach USD 6.88 Billion by 2036, witnessing around 2.3% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of gastroesophageal reflux disease is estimated at USD 5.24 Billion. The rising prevalence of gastrointestinal diseases over the world is set to propel the growth of the market. Recent statistics of WHO, in 2022 revealed that for every ten adults in the world, four suffer from functional gastrointestinal disorders.

The global gastroesophageal reflux disease market size is projected to also increase on account of increased awareness of the disease across the globe. Furthermore, the changing lifestyle of people toward sedentary behavior and the increasing tendency to self-medicate is also positively impacting the growth of the market. The availability of a strong medication pipeline is also slated to fuel the market gain.

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of gastroesophageal reflux disease is estimated at USD 5.24 Billion.

The gastroesophageal reflux disease (GERD) market size was over USD 5.12 Billion in 2023 and is anticipated to reach USD 6.88 Billion by 2036, witnessing around 2.3% CAGR during the forecast period i.e., between 2024-2036. Higher consumption of processed food, increase in digestive issues, and problems caused by contaminated food are the few factors likely to propel the market growth.

North America industry is projected to hold 35% of the revenue share in the 2036, owing to rising aging population in the region which are more prone to gastrointestinal problems.

AstraZeneca PLC, Eisai Co., Ltd., GSK plc., Takeda Pharmaceutical Company Limited., Ironwood Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., SFJ Pharmaceuticals, Sebela Pharmaceuticals, Phathom Pharmaceuticals, Inc., Camber Pharmaceuticals, Inc.

Gastroesophageal Reflux Disease Market Size